Evidence map›Paper›PMID 19244369›Full record

Trial reportThe American journal of clinical nutrition2009

Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids.

Sandra C van Calcar, Erin L MacLeod, Sally T Gleason, Mark R Etzel, Murray K Clayton, Jon A Wolff, Denise M Ney

Erratum issued Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01428258 (Phase 2 Study of Glycomacropeptide vs. Amino Acid Diet for the Management of PKU), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01428258 nacompletednot on this mapstarted 2011, after this paper: background citation

Phase 2 Study of Glycomacropeptide vs. Amino Acid Diet for the Management of PKU

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2011 to 2016Enrolled32ConditionsPhenylketonuriaArmsGMP Diet/GMP Medical Foods, AA Diet/AA Medical Foods
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sandra C van CalcarWaisman Center, University of Wisconsin, Madison, WI 53706, USA.
Erin L MacLeod
Sally T Gleason
Mark R Etzel
Murray K Clayton
Jon A Wolff
Denise M Ney
University of Wisconsin–Madison · US

Funding

INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
WISCONSIN CENTER ON MENTAL RETARDATION: CORE SUPPORTP30HD003352 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI DAVIDSON, RICHARD J · 1985 to 2015
$25.2M
Dietary Control of PKU with Glycomacropeptide from WheyR03DK071534 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI NEY, DENISE M · 2005 to 2007
$308k
NCRR NIH HHS 1UL1 RR 025011NICHD NIH HHS P30-HD-03352NIDDK NIH HHS R03 DK071534NIDDK NIH HHS R03-DK-071534
6 · The paper itself

Abstract

backgroundPhenylketonuria (PKU) requires a lifelong low-phenylalanine diet that provides the majority of protein from a phenylalanine-free amino acid (AA) formula. Glycomacropeptide (GMP), an intact protein formed during cheese production, contains minimal phenylalanine.

objectiveThe objective was to investigate the effects of substituting GMP food products for the AA formula on acceptability, safety, plasma AA concentrations, and measures of protein utilization in subjects with PKU.

designEleven subjects participated in an inpatient metabolic study with two 4-d treatments: a current AA diet (AA diet) followed by a diet that replaced the AA formula with GMP (GMP diet) supplemented with limiting AAs. Plasma concentrations of AAs, blood chemistries, and insulin were measured and compared in AA (day 4) and GMP diets (day 8).

resultsThe GMP diet was preferred to the AA diet in 10 of 11 subjects with PKU, and there were no adverse reactions to GMP. There was no significant difference in phenylalanine concentration in postprandial plasma with the GMP diet compared with the AA diet. When comparing fasting with postprandial plasma, plasma phenalyalanine concentration increased significantly with the AA but not with the GMP diet. Blood urea nitrogen was significantly lower, which suggests decreased ureagenesis, and plasma insulin was higher with the GMP diet than with the AA diet.

conclusionsGMP, when supplemented with limiting AAs, is a safe and highly acceptable alternative to synthetic AAs as the primary protein source in the nutritional management of PKU. As an intact protein source, GMP improves protein retention and phenylalanine utilization compared with AAs.

Indexed as

AdolescentAdultAmino AcidsBlood Chemical AnalysisBlood Urea NitrogenChildConsumer Product SafetyCross-Over StudiesFemaleGlycopeptidesHumansInsulinMalePatient SatisfactionPhenylalaninePhenylketonuriasAmino AcidsGlycopeptidesInsulinPhenylalanine

Identifiers

PMID19244369
PMCPMC2667457
OpenAlexW2107406829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.